Xilio Development

Yahoo Finance • 2 months ago

Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2025 Financial Results

Reported late-breaking Phase 2 data at SITC for vilastobart demonstrating a 40% ORR in heavily pretreated patients with MSS mCRC without liver metastases and high plasma tumor mutational burden Presented Phase 1 data at SITC for efarindod... Full story

Yahoo Finance • 2 months ago

Xilio Therapeutics Announces Late-Breaking Phase 2 Data for Vilastobart in Patients with MSS mCRC and High Plasma Tumor Mutational Burden at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting

40% ORR in heavily pre-treated patients with MSS mCRC without liver metastases and with high plasma tumor mutational burden (TMB) Estimate 55% of patients with MSS CRC have high plasma TMB, representing a meaningful population with high u... Full story

Yahoo Finance • 2 months ago

Xilio Therapeutics Highlights Portfolio of Differentiated Masked Immunotherapies at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting

Preclinical data support best-in-class potential of masked T cell engager programs and platform utilizing Xilio’s ATACR and SEECR formats, including efficient masking, potent anti-tumor activity and broad therapeutic index Phase 1 data fo... Full story

Yahoo Finance • 3 months ago

Xilio Therapeutics to Present Phase 2 Data for Vilastobart Highlighting Response Rate in Patients with MSS mCRC and High Plasma Tumor Mutational Burden as a Late-Breaking Presentation at SITC 40th Annual Meeting

WALTHAM, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today an... Full story

Yahoo Finance • 3 months ago

Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting

WALTHAM, Mass., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today an... Full story

Yahoo Finance • 3 months ago

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today an... Full story

Yahoo Finance • 5 months ago

Xilio Development earnings missed by $0.06, revenue topped estimates

Investing.com - Xilio Development (NASDAQ: XLO) reported second quarter EPS of $-0.160, $0.06 worse than the analyst estimate of $-0.100. Revenue for the quarter came in at $8.21M versus the consensus estimate of $7.4M. Xilio Developmen... Full story

Yahoo Finance • 5 months ago

Xilio Therapeutics GAAP EPS of -$0.16 misses by $0.06

* Xilio Therapeutics press release [https://seekingalpha.com/pr/20200828-xilio-therapeutics-announces-pipeline-and-business-updates-and-second-quarter-2025-financial] (NASDAQ:XLO [https://seekingalpha.com/symbol/XLO]): Q2 GAAP EPS of -$0... Full story

Yahoo Finance • 5 months ago

Catalyst Pharmaceuticals Appoints Daniel Curran, MD, to its Board of Directors

CORAL GABLES, Fla., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today announced the appointment of Daniel Curran, MD, to its Board of Directors. Dr. Curran is a distinguished... Full story

Yahoo Finance • 6 months ago

Bristol Myers Squibb and Bain Capital Form New Immunology Company

The company will begin with five potential treatments for autoimmune diseases in-licensed from Bristol Myers Squibb, which will retain 20% equity in the new company. Continue Reading View Comments... Full story

Yahoo Finance • 6 months ago

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass., July 02, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today an... Full story

Yahoo Finance • 7 months ago

Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to its Board of Directors

WALTHAM, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today an... Full story

Yahoo Finance • 7 months ago

Xilio Therapeutics Announces Closing of $50.0 Million Public Offering

Total gross proceeds of up to $150.0 million before the end of 2026 if all Series B warrants and Series C warrants are exercised for cash Xilio may elect to cancel unexercised Series B or Series C warrants proportionately to the amount of... Full story

Yahoo Finance • 7 months ago

Xilio Therapeutics Announces Pricing of $50.0 Million Public Offering

WALTHAM, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today an... Full story

Yahoo Finance • 7 months ago

Xilio Therapeutics announces public offering; shares down

* Xilio Therapeutics (NASDAQ:XLO [https://seekingalpha.com/symbol/XLO]) announced an underwritten public offering of pre-funded warrants and Series A, B, and C warrants to purchase shares of common stock. * All the securities to be sol... Full story

Yahoo Finance • 7 months ago

Xilio Therapeutics Announces Proposed Public Offering

WALTHAM, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today an... Full story

Yahoo Finance • 8 months ago

Xilio Therapeutics Announces Updated Phase 2 Data for Vilastobart, a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer

26% preliminary objective response rate observed in heavily pre-treated patients with metastatic microsatellite stable colorectal cancer (MSS CRC) without liver metastases Deep and durable responses ongoing for up to 37 weeks through the... Full story

Yahoo Finance • 8 months ago

Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass., May 02, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today ann... Full story

Yahoo Finance • 9 months ago

Xilio Therapeutics to Present Updated Phase 2 Data for Vilastobart, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Combination with Atezolizumab in Patients with Microsatellite Stable Colorectal Cancer at the 2025 ASCO Annual Meeting

WALTHAM, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today a... Full story

Yahoo Finance • 10 months ago

Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2024 Financial Results

Additional Phase 2 data for vilastobart,a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab in patients with MSS CRC anticipated in the middle of 2025 Advancing masked T cell engager programs in novel ATACR and SE... Full story